The Treatment of Inflammatory Facial Dermatoses With Topical Corticosteroids: Focus on Clocortolone Pivalate 0.1% Cream

October 2012 | Volume 11 | Issue 10 | Original Article | 1194 | Copyright © October 2012

matitis and psoriasis proved to be effective and safe over short courses of therapy for disease flares. In the study reported here, clocortolone pivalate 0.1% cream was effective and safe for the treatment of facial seborrheic dermatitis, atopic dermatitis, and psoriasis. The clocortolone pivalate molecule exhibits unique structural characteristics that impact upon efficacy and may also modify AEs in an advantageous manner. The distinctive halogen positioning and pivalate group produce a TC in the upper end of the mid-potency range. In addition, the cream formulation of clocortolone pivalate, contains three emollient ingredients (white petrolatum, mineral oil, stearyl alcohol) and is devoid of fragrance, propylene glycol, and lanolin, all factors that are favorable when treating inflamed or eczematous skin.


Dr. Kircik serves as as advisor, investigator, consultant, and speaker for Bayer, Galderma, Promius, Stiefel, GSK, LeoPharma, Taro, and Valeant. Dr. Del Rosso has served as an advisor or consultant for: Allergan; Bayer Dermatology; Dermira; Galderma; LeoPharma; Medicis; Onset Therapeutics; Pharmaderm; Primus, Promius, Ranbaxy; Taro; TriaBeauty; Unilever; Valeant/Coria Dermatology, Warner Chilcott. Dr. Del Rosso has served as a speaker or a member of a speakers bureau for: Allergan; Bayer Dermatology; Galderma; LeoPharma; Medicis; Onset Therapeutics; Pharmaderm; Promius; Taro; TriaBeauty; Unilever; Valeant/Coria Dermatology, Warner Chilcott. Dr. Del Rosso has received grants for clinical research from: Allergan, Inc.; Amgen; Coria Laboratories, Ltd.; Galderma Laboratories, L.P.; Intendis Inc.; Medicis Pharmaceutical Corporation; Graceway Pharmaceuticals, LLC; Ortho Dermatology; Onset Therapeutics; Stiefel Laboratories Inc.; Triax Pharmaceuticals; Warner Chilcott. Dr. Del Rosso has no relevant stock ownership.


  1. van de Kerkhof PC, Murphy GM, Austad J, et al. Psoriasis of the face and flexures. J Dermatog Treat. 2007;18(6):351-60.
  2. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24:985-994.
  3. Tagami, H. Location-related differences in structure and function of the stratum corneum with special emphasis on those of the facial skin. Int J Cosmetic Sci. 2008;30:413-434.
  4. Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol. 2009;161:427-434.
  5. Del Rosso JQ, Kircik L, Clocortolone pivalate 0.1% cream, JCAD , July 2012.
  6. Freeman S, Howard A, Foley P, et al. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen®) versus vehicle in the short-term treatment of facial atopic or seborrheic dermatitis. Australas J Dermatol. 2002;43:186-189.
  7. Papp KA, Papp BA, Dahmer B, et al. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol. Epub. 10.1016/j.jaad.2011.02.032.
  8. Kircik LH. Treatment of scalp and facial seborrheic dermatitis with desonide hydrogel 0.05%. J Clin Aesthetic Dermatol. 2009;2:32-36.
  9. Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb® Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clinics in Dermatology. 2009;27:S39-S40.
  10. Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142:1066-1067.
  11. Stratigos JD, Antoniou C, Katsambas A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. J Am Acad Dermatol. 1988;19(5 Pt 1):850-853.
  12. Nierman, MM. Safety and efficacy of clocortolone pivalate 0.1% cream, a new topical steroid in atopic dermatitis, contact dermatitis, and seborrheic dermatitis. Presented at North American Clinical Dermatological Society, March 1980. Data on file, Promius Pharma, LLC.
  13. Bikowski J. Facial seborrheic dermatitis: a report on current status and therapeutic horizons. J Drugs Dermatol. 2009;8:125-133.
  14. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20:407-416.
  15. Nivenius E, van der Ploeg I, Jung K, et al. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye. 2007;21:968-975.
  16. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Experiment Ophthalmol. 2004;32:224-226.
  17. Sahni D, Darley CR, Hawk JL. Glaucoma induced by periorbital topical steroid use - a rare complication. Clin Exp Dermatol. 2004;29:617-619.
  18. Haeck IM, Rouwen TJ, Timmer-de Mik L, et al. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol. 2011;64(2):275-281.
  19. Lebwohl MG, Tan MH, Meador SL, et al. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol. 2001;44:77-82.


Leon H. Kircik MDPhysicians Skin Care, PLLC1169 Eastern Parkway Suite 2310Louisville, KY